Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Targeting Metabolic Disorders With Advinus Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement marks Merck’s first research collaboration in India.

You may also be interested in...



Phase II “Baby Boom” A Mixed Blessing

New era calls for sharper scrutiny and creative deals, Windhover panel says.

Phase II “Baby Boom” A Mixed Blessing

New era calls for sharper scrutiny and creative deals, Windhover panel says.

India’s Advinus Signs On With Genzyme In Malaria Research

Development of malaria drugs could qualify Genzyme for a priority review voucher under FDA’s tropical disease incentive.

Related Content

Topics

UsernamePublicRestriction

Register

PS063384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel